MK-2870-005 |
Cancer Trials Ireland |
Mater Misericordiae Hospital |
Participants with Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Immunotherapy |
The Sleepio After Cancer (SAC) Study |
SAC Study |
The SAC study is recruiting participants from the Mater University Hospital and St Vincent’s University Hospital, Dublin |
The SAC study is recruiting women over the age of 18 with a history of cancer (currently having treatment or having completed treatment), who are having difficulty with their sleep. |
ENGOT en23 / PREVENTER |
Cancer Trials Ireland |
St. James’s Hospital, Dublin (opening shortly) Cork University Hospital, Cork (currently) Mater Misericordiae Hospital (currently) |
• Has a histologically-confirmed diagnosis of endometrial carcinoma or carcinosarcoma. • Has radiographically evaluable disease. • Has received prior platinum-based chemotherapy and anti-programmed cell death 1 protein (PD-1)/anti- programmed cell death ligand 1 (PD-L1) therapy, either separately or in combination. |
OVHIPEC-2 |
Cancer Trials Ireland |
Mater Hospital (currently) |
This trial is open to females aged 18 years or older who have a formal diagnosis from their doctor of epithelial ovarian, fallopian tube, or extra-ovarian cancer. Epithelial ovarian cancer is a type of cancer that originates in the cells covering the surface of the ovaries. In Stage III, the cancer typically extends beyond the ovaries and may involve the pelvic organs, such as the fallopian tubes or the lining of the abdominal cavity. It may also involve nearby lymph nodes. |
XPORT-EC |
Cancer Trials Ireland |
St. James’s Hospital, Dublin (currently) Cork University Hospital, Cork (currently) University Hospital Galway (currently) University Hospital Waterford (currently) Beacon Hospital (opening soon) |
• Age 18 years or above • Histologically confirmed Endometrial Cancer including: endometrioid, serous, undifferentiated, and carcinosarcoma. • TP53 wildtype • Completed a single line, at least 12 weeks of platinum-based therapy (not including adjuvant or neoadjuvant therapy for Stage I-III disease) • Achieved confirmed partial or complete response. |
NRG GY019 |
Cancer Trials Ireland |
St. James’s Hospital, Dublin (currently) Cork University Hospital, Cork (opening soon) |
• Newly diagnosed, stage II-IV low-grade serous ovarian cancer. • nonaberrant p53 expression • Age >= 18 • Patients must have undergone an attempt at maximal upfront cytoreductive surgery • Patients must have both ovaries and fallopian tubes removed • Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 |
HELP-ER |
Cancer Trials Ireland |
Beacon Hospital (currently) |
Patients with first relapse ovarian cancer |